Positron-emission-tomography in tubercular lymphadenopathy: A study on its role in evaluating post-treatment response

Abhishek Singh1, Madhavi Tripathi2, Parul Kodan1, Nitin Gupta1, Neeraj Nischal1*, Pankaj Jorwal1, Arvind Kumar1, Animesh Ray1, Manish Soneja1, Naveet Wig1

1 Department of Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India; 2 Department of Nuclear Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India.

SUMMARY Lymph node tuberculosis is one of the most common forms of extrapulmonary tuberculosis worldwide. The study aimed to evaluate the role of positron emission tomography-computed tomography (PET-CT) in determining post-treatment response in lymph node tuberculosis. A PET-CT was done in all treatment naïve tubercular lymphadenitis adults at baseline and after six months of therapy. The post-treatment clinical response was compared with the metabolic response on PET-CT. Of the 25 patients with tubercular lymphadenitis, 9/25 patients showed a complete metabolic response (CMR) at six months, while 16 patients had a partial metabolic response (PMR). All patients with CMR had a good clinical response. However, discordance between clinical and PET findings was noticed in those with PMR. The role of PET-CT in evaluating post-treatment response in patients with tubercular lymphadenitis needs further evaluation with a larger sample size.

Keywords FDG PET-CT, lymph-node, tuberculosis

1. Introduction

Tuberculosis has affected humanity since ages and continues to be a significant global public health epidemic even today (1). Extrapulmonary tuberculosis (EPTB) forms a substantial proportion of the total number of cases (2-4). Lymph node tuberculosis (LNTB) has been reported as the most frequent form of EPTB, with an incidence of 30.8 per 100,000 population (3). The management of lymph node tuberculosis is a challenging ordeal as many patients continue to have persistent swelling despite the prescribed duration of treatment. Often, the endpoint of therapy is difficult to determine objectively (4). The present guidelines of LNTB have been mainly extrapolated from experience with pulmonary tuberculosis. The duration of treatment in tubercular lymphadenitis is usually guided by a clinical response alone. There is a need for a more accurate objective tool for evaluating response to therapy in patients with LNTB. This study aimed to determine the role of positron emission tomography-computed tomography (PET-CT) in assessing the treatment responses in patients with LNTB.

2. Materials and Methods

This is a prospective study in which treatment naïve adults (> 14 years of age) diagnosed as LNTB were enrolled in the study after taking written informed consent. Patients with significant comorbidities (malignancy, immunosuppression) were excluded from the study. Pregnant and lactating females were also excluded. An approval from the Institute Ethics Committee was obtained before the study was initiated (IECPG/384/29.06.2016). Clinical findings and baseline laboratory investigations were noted for all patients. A PET-CT scan (pre-therapy) was done at the baseline before the initiation of treatment. The treatment for lymph node tuberculosis was guided by the national guidelines for lymph node tuberculosis (2). A repeat PET-CT (post-therapy) was done after six months for all the recruited patients. Before the post-therapy scan was done, they were classified to have "complete clinical response (CCR)" or "partial clinical response (PCR)" based on the resolution of clinical symptomatology by a team of expert clinicians not involved in the treatment process. After the post-therapy scan was done, the images were analyzed and reported by two nuclear medicine physicians blinded to the clinical response. Anatomical regions and the total number of sites of abnormal tracer accumulation were noted. Based on the pre-therapy scan and post-therapy scan parameters, the patients were classified to have "complete metabolic response (CMR)" and "partial metabolic response
Table 1. Clinical, laboratory and radiological features of the study population

| Variable                        | N (%) |
|---------------------------------|-------|
| **Variable**                    |       |
| A Clinical Features             |       |
| 1 Fever                         | 20 (80) |
| 2 Cough                         | 19 (76) |
| 3 Weight loss                   | 15 (60) |
| 4 Neck swelling                 | 12 (48) |
| 5 Abdominal pain                | 9 (36)  |
| 6 Chest pain                    | 6 (24)  |
| 7 Back pain                     | 5 (20)  |
| B Radiological manifestations (PET/CT) |       |
| 1 Cervical                      | 19 (76) |
| 2 Mediastinal                   | 20 (80) |
| 3 Abdominal                     | 10 (40) |
| 4 Pelvic                        | 5 (20)  |
| 5 Extra-nodal                   | 8 (40)  |
| 6 Necrotic lymphnodes           | 22 (88) |
| C Cytopathological Diagnosis of TB |       |
| 1 Necrotizing granuloma         | 20 (80) |
| D Microbiological Diagnosis     |       |
| 1 AFB positive                  | 3 (12)  |
| 2 CB-NAAT (Gene-Xpert) positive | 9 (36)  |
| 3 MGIT Culture positive         | 3 (12)  |

Table 2. Patient characteristics, PET/CT findings and imaging and clinical outcome in 25 patients

| Study No | Sex | Age | Station                          | Mode of diagnosis | Metabolic response | Clinical Response |
|----------|-----|-----|----------------------------------|-------------------|--------------------|-------------------|
| 1        | F   | 74  | Cervical, Abdominal             | Microbiological   | Partial            | Complete          |
| 2        | F   | 24  | Cervical, Mediastinal, Extra-nodal | Histology         | Partial            | Complete          |
| 3        | F   | 20  | Cervical, Mediastinal, Extrane | Microbiological   | Complete           | Complete          |
| 4        | F   | 36  | Mediastinal                     | Microbiological   | Partial            | Complete          |
| 5        | M   | 23  | Mediastinal                     | Microbiological   | Complete           | Complete          |
| 6        | M   | 37  | Mediastinal, Pelvic             | Histology         | Complete           | Complete          |
| 7        | F   | 32  | Cervical                        | Microbiological   | Partial            | Partial           |
| 8        | F   | 18  | Pelvic, Extraneodal             | Radiological      | Partial            | Complete          |
| 9        | F   | 23  | Cervical, Mediastinal           | Histology         | Partial            | Complete          |
| 10       | M   | 70  | Cervical, Mediastinal           | Radiological      | Partial            | Partial           |
| 11       | M   | 28  | Mediastinal                     | Histology         | Complete           | Complete          |
| 12       | M   | 19  | Cervical, Mediastinal           | Microbiological   | Complete           | Complete          |
| 13       | F   | 30  | Cervical, Abdominal             | Histology         | Complete           | Complete          |
| 14       | F   | 20  | Mediastinal                     | Radiology         | Partial            | Partial           |
| 15       | M   | 19  | Cervical, Mediastinal, Abdominal, Pelvic, extra-nodal | Microbiological | Complete           | Complete          |
| 16       | M   | 30  | Cervical                        | Histology         | Complete           | Complete          |
| 17       | F   | 15  | Cervical, Mediastinal, Abdominal, Pelvic | Histology | Partial            | Partial           |
| 18       | F   | 14  | Cervical, Mediastinal, Abdominal, Extra-nodal | Histology       | Partial            | Complete          |
| 19       | M   | 28  | Cervical, Mediastinal, Abdominal, Pelvic | Histology       | Partial            | Partial           |
| 20       | M   | 47  | Cervical, Mediastinal, Extra-nodal | Histology         | Complete           | Complete          |
| 21       | M   | 22  | Cervical, Mediastinal, Abdominal, Extra-nodal | Microbiological | Partial            | Partial           |
| 22       | F   | 28  | Cervical, Mediastinal, Abdominal, Extra-nodal | Histology         | Partial            | Partial           |
| 23       | M   | 35  | Cervical, Mediastinal, Abdominal, Pelvic, Extraneodal | Microbiological | Partial            | Complete          |
| 24       | M   | 18  | Cervical, Mediastinal           | Histology         | Partial            | Complete          |
| 25       | M   | 32  | Cervical, Mediastinal, Abdominal | Microbiological   | Partial            | Complete          |
was seen in 16/25 patients, nine of these patients showed a CCR and their treatment was stopped. The remaining seven patients with PMR and PCR were continued on therapy for a variable range of duration. All patients were followed up until the end of the study period. None of the patients with CCR (including 9 with CMR and 9 with PMR) relapsed until the end of the follow-up period. The mean duration of follow-up after completion of treatment was 127 +/- 57 days.

SUV max of lymph nodes for both the scans was computed. The percentage change in standardized uptake value (ΔSUV-max) was analyzed between baseline PET and the scan after six months of treatment. The changes in the SUV-max values were statistically significant in cervical and mediastinal lymph node stations with a p-value of 0.043 and 0.006, respectively. However, abdominal lymph nodes did not show a statistically significant change. A receiver operating characteristic (ROC) curve analysis was done to analyze the diagnostic utility of the percent change in SUV-max as a marker of clinical response to treatment in patients with cervical/mediastinal lymph nodes. A change in 77% or more in the SUV-max of cervical lymph nodes had a sensitivity and specificity of 75% (95%CI: 42.8-94.5%) and 100% (95%CI: 47.8-100%) respectively in predicting clinical response. A change in 52% or more in the SUV-max of mediastinal lymph nodes had a sensitivity and specificity of 75% (95%CI: 47.6-92.7%) and 100% (95%CI: 54.1-100%) respectively in predicting clinical response.

FDG PET-CT is increasingly being used for diagnosis and guiding therapeutic decisions in patients with infectious diseases. The available literature on FDG/PET-CT for assessing results and treatment response in patients with pulmonary TB is limited and suggests a good correlation between the two of them (5). However, there is a paucity of literature evaluating FDG/PET-CT’s role in EPTB in particular. PET-CT has been hypothesized to predict the need for treatment intensification or prolonged therapeutic strategies or change in the treatment regimen (6). Experimental animal models have shown that FDG PET-CT activity seems to be in direct correlation to the bactericidal activity of anti-tuberculosis treatment (7,8).

It is pertinent to note that FDG uptake is based on the glycolytic activity in the neutrophils, lymphocytes and macrophages and represents inflammation (9,10). Therefore, the absence of uptake suggests a decrease in inflammation, suggesting that the patient has responded to treatment. This is the reason why in patients with no metabolic uptake in the post-therapy scans had all responded clinically. It is evident from our results that the persisting activity may not suggest active disease. In such cases, clinical assessment should be given more importance in deciding the course of action (11-18). Similar to a previously published study, our study showed that change in SUV-max could be used as a surrogate for predicting clinical response as well (15). We found that percentage decrease of 77% for cervical lymph nodes and 52% decrease for mediastinal lymph nodes had excellent specificity and considerable sensitivity. However, there is a need for a larger sample size to validate the cut-offs that we derived.

In conclusion, although PET may be useful as an adjunct to clinical response in guiding duration of therapy in some cases of tubercular lymphadenitis, its routine use as a stand-alone guide for treatment response needs to be ascertained with further studies with larger sample size.

Funding: None.

Conflict of Interest: The authors have no conflicts of interest to disclose.

References

1. Furin J, Cox H, Pai M. Tuberculosis. Lancet. 2019; 393:1642-1656.

www.ddtjournal.com
2. Sharma SK, Ryan H, Khaparde S, Sachdeva KS, Singh AD, Mohan A, Sarin R, Paramasivam CN, Kumar P, Nischal N, Khatiwada S, Garner P, Tharyan P. Index-TB guidelines: Guidelines on extrapulmonary tuberculosis for India. Indian J Med Res. 2017; 145:448-463.

3. Sharma SK, Mohan A. Extra-pulmonary tuberculosis. Indian J Med Res. 2004; 120:316-353.

4. Fontanilla JM, Barnes A, Von Reyn CF. Current diagnosis and management of peripheral tuberculous lymphadenitis. Clin Infect Dis. 2011; 53:555-562.

5. Kim JJ, Lee JS, Kim SJ, Kim YK, Jeong YJ, Jun S, Nam HY, Kim JS. Double-phase 18F-FDG PET-CT for determination of pulmonary tuberculoma activity. Eur J Nucl Mol Imaging. 2008; 35:808-814.

6. Kosterink JGW. Positron emission tomography in the diagnosis and treatment management of tuberculosis. Curr Pharm Des. 2011; 17:2875-2880.

7. Ichiya Y, Kuwabara Y, Sasaki M, Yoshida T, Akashi Y, Murayama S, Nakamura K, Fukumura T, Masuda K. FDG-PET in infectious lesions: The detection and assessment of lesion activity. Ann Nucl Med. 1996; 10:185-191.

8. Sathekge M, Maes A, Kgomo M, Stoltz A, Pottel H, Van de Wiele C. Impact of FDG PET on the management of TBC treatment. A pilot study. Nucl Nucl Med. 2010; 49:35-40.

9. Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ, Israel O, Martin-Comin J, Signore A. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med. 2013; 54:647-658.

10. Soussan M, Brillet PY, Mekinian A, Khaifagy A, Nicolas P, Vessieres A, Brauner M. Patterns of pulmonary tuberculosis on FDG-PET/CT. Eur J Radiol. 2012; 81:2872-2876.

11. Bakheet SM, Powe J, Ezzat A, Rostom A. F-18-FDG uptake in tuberculosis. Clin Nucl Med. 1998; 23:739-742.

12. Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y, Yanagihara K, Li M, Tanaka F, Wada H, Manabe T, Saga T. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia. 2005; 7:369-379.

13. Goo JM, Im JG, Do KH, Yeo JS, Seo JB, Kim HY, Chung JK. Pulmonary tuberculoma evaluated by means of FDG PET: Findings in 10 cases. Radiology. 2000; 216:117-121.

14. Demura Y, Tsuchida T, Uesaka D, Umeda Y, Morikawa M, Ameshima S, Ishizaki T, Fujibayashi Y, Okazawa H. Usefulness of 18F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur J Nucl Med Mol Imaging. 2009; 36:632-639.

15. Sathekge M, Maes A, D'Asseler Y, Vorster M, Gongxeka H, Van de Wiele C. Tuberculous lymphadenitis: FDG PET and CT findings in responsive and nonresponsive disease. Eur J Nucl Med Mol Imaging. 2012; 39:1184-1190.

16. Tian G, Xiao Y, Chen B, Xia J, Guan H, Deng Q. FDG PET/CT for therapeutic response monitoring in multi-site non-respiratory tuberculosis. Acta Radiol. 2010; 51:1002-1006.

17. Sathekge M, Maes A, Kgomo M, Stoltz A, Van de Wiele C. Use of 18F-FDG PET to predict response to first-line tuberculosis in HIV-associated tuberculosis. J Nucl Med. 2011; 52:880-885.

18. Vorster M, Sathekge MM, Bomanji J. Advances in imaging of tuberculosis: the role of 18F-FDG PET and PET/CT. Curr Opin Pulm Med. 2014; 20:287-293.

Received June 6, 2020; Revised February 9, 2021; Accepted February 25, 2021.

*Address correspondence to:
Neeraj Nischal, Department of Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
E-mail: neerajnischal@gmail.com

Released online in J-STAGE as advance publication February 27, 2021.